Summary & Overview
HCPCS J0873: Daptomycin (Xellia) Injection, 1 mg
HCPCS Level II code J0873 denotes a 1 mg unit of injectable daptomycin (Xellia), a parenteral antibiotic used for serious Gram-positive infections. As a distinct formulation identified as not therapeutically equivalent to other daptomycin HCPCS codes, J0873 matters nationally for hospital and infusion billing, drug utilization tracking, and payer coverage policies. Accurate coding supports correct drug identification, billing accuracy, and clinical inventory control.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context and typical sites of service, plus national benchmarking considerations and payer coverage implications where available. The publication outlines common billing practices for parenteral antimicrobials, identifies coding distinctions tied to formulation and therapeutic equivalence, and summarizes the types of information payers use when adjudicating claims for high-cost injectable drugs.
This summary is intended for billing managers, revenue cycle staff, pharmacy directors, and policy analysts seeking a clear reference for J0873 coding, billing context, and where to look for payer-specific policy updates. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J0873 describes an injectable formulation of daptomycin (Xellia) billed per 1 mg unit. The description specifies that this product is not therapeutically equivalent to J0878 or J0872, indicating a distinct branded or sourced formulation.
Service Type: Intravenous antimicrobial injection
Typical Site of Service: Hospital inpatient, hospital outpatient, and other infusion settings
Clinical & Coding Specifications
Clinical Context
A typical patient is a hospitalized adult with a confirmed gram-positive bloodstream infection, complicated skin and soft tissue infection, or infective endocarditis caused by organisms susceptible to daptomycin (for example, methicillin-resistant Staphylococcus aureus). Inpatient infectious disease consultation recommends parenteral daptomycin when vancomycin is contraindicated (eg, renal toxicity, intolerance) or when pathogen susceptibility or clinical response warrants. Pharmacy prepares weight‑based doses (commonly 4–10 mg/kg IV daily) of J0873 billed per milligram; the drug is administered as an intravenous infusion or slow IV push per institutional protocol, with monitoring of creatine phosphokinase and renal function. Typical workflow: order entry by the treating team, pharmacy compounding and verification, bedside nursing administration, documentation of dose and lot number, and monitoring for adverse effects. Doses are commonly given in inpatient acute care hospitals, observation units, and occasionally in outpatient infusion clinics for continuation therapy. Patient scenarios include a 68‑year‑old with MRSA bacteremia intolerant of vancomycin or a 55‑year‑old with complicated cellulitis and bacteremia requiring hospital-based IV antibiotic therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard billing when no modifier applies |